Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases

Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurrent and severe infections, which cause lung damage and shorten their life span. Immu...

Descripción completa

Detalles Bibliográficos
Autor principal: Kobrynski, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430092/
https://www.ncbi.nlm.nih.gov/pubmed/22956859
http://dx.doi.org/10.2147/BTT.S25188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430092/
https://www.ncbi.nlm.nih.gov/pubmed/22956859
http://dx.doi.org/10.2147/BTT.S25188

Ejemplares similares